Trial Outcomes & Findings for Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) (NCT NCT03259087)

Results Overview

Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

42 participants

Primary outcome timeframe

Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Results posted on

2019-04-19

Participant Flow

Participant milestones

Participant milestones
Measure	Part 1: Mild Renal Impairment (RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 2: End-stage Renal Disease Undergoing Hemodialysis End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
Part 1 and Period 1 of Part 2 STARTED	8	8	8	10	8
Part 1 and Period 1 of Part 2 COMPLETED	8	8	8	10	7
Part 1 and Period 1 of Part 2 NOT COMPLETED	0	0	0	0	1
Period 2 of Part 2 STARTED	0	0	0	0	7
Period 2 of Part 2 COMPLETED	0	0	0	0	6
Period 2 of Part 2 NOT COMPLETED	0	0	0	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Mild Renal Impairment (RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 2: End-stage Renal Disease Undergoing Hemodialysis End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
Part 1 and Period 1 of Part 2 Adverse Event	0	0	0	0	1
Period 2 of Part 2 Adverse Event	0	0	0	0	1

Baseline Characteristics

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants n=10 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 2: End-stage Renal Disease Undergoing Hemodialysis n=8 Participants End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.	Total n=42 Participants Total of all reporting groups
Age, Continuous	68.3 Years STANDARD_DEVIATION 5.65 • n=5 Participants	67.0 Years STANDARD_DEVIATION 9.24 • n=7 Participants	57.3 Years STANDARD_DEVIATION 13.83 • n=5 Participants	61.2 Years STANDARD_DEVIATION 8.36 • n=4 Participants	51.9 Years STANDARD_DEVIATION 8.68 • n=21 Participants	61.1 Years STANDARD_DEVIATION 10.83 • n=8 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	15 Participants n=8 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	5 Participants n=21 Participants	27 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	1 Participants n=21 Participants	15 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants	6 Participants n=4 Participants	7 Participants n=21 Participants	27 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	7 Participants n=21 Participants	15 Participants n=8 Participants
Race (NIH/OMB) White	6 Participants n=5 Participants	6 Participants n=7 Participants	5 Participants n=5 Participants	8 Participants n=4 Participants	1 Participants n=21 Participants	26 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Body Mass Index	28.125 kg/m^2 n=5 Participants	27.625 kg/m^2 n=7 Participants	28.625 kg/m^2 n=5 Participants	28.800 kg/m^2 n=4 Participants	29.875 kg/m^2 n=21 Participants	28.619 kg/m^2 n=8 Participants

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)	104 µM*hr Interval 87.2 to 125.0	141 µM*hr Interval 115.0 to 174.0	83.5 µM*hr Interval 75.0 to 92.9	244 µM*hr Interval 169.0 to 352.0	81.8 µM*hr Interval 72.4 to 92.4	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to the Time of the Last Quantifiable Sample (AUC0-last)	103 µM*hr Interval 86.7 to 123.0	139 µM*hr Interval 114.0 to 170.0	83.0 µM*hr Interval 74.5 to 92.5	237 µM*hr Interval 166.0 to 338.0	81.4 µM*hr Interval 72.0 to 92.0	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to 24 Hours After Dosing (AUC0-24)	96.2 µM*hr Interval 82.0 to 113.0	127 µM*hr Interval 107.0 to 152.0	79.7 µM*hr Interval 71.6 to 88.7	182 µM*hr Interval 136.0 to 243.0	78.1 µM*hr Interval 69.2 to 88.3	—

PRIMARY outcome

Timeframe: At the end of the infusion (0.5 hours after infusion start) on Day 1

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Plasma Concentration of MK-3866 at the End of the Infusion (Ceoi)	26.6 µM Interval 22.3 to 31.8	27.7 µM Interval 24.2 to 31.7	27.0 µM Interval 23.9 to 30.5	29.7 µM Interval 25.4 to 34.7	26.9 µM Interval 23.7 to 30.5	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the combined comparator experimental groups.

Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=10 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Maximum Plasma Concentration of MK-3866 (Cmax)	27.4 µM Interval 26.0 to 28.9	28.0 µM Interval 26.4 to 29.7	28.7 µM Interval 26.4 to 31.2	26.7 µM Interval 24.8 to 28.8	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Plasma Clearance of MK-3866 (CL)	3.80 L/hr Interval 3.17 to 4.55	2.80 L/hr Interval 2.28 to 3.44	4.75 L/hr Interval 4.27 to 5.28	1.62 L/hr Interval 1.12 to 2.35	4.85 L/hr Interval 4.29 to 5.48	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Time to Maximum Plasma Concentration of MK-3866 (Tmax)	0.50 Hours Interval 0.47 to 0.5	0.49 Hours Interval 0.47 to 0.5	0.50 Hours Interval 0.47 to 0.5	0.50 Hours Interval 0.47 to 0.53	0.50 Hours Interval 0.47 to 0.5	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric % coefficient of variation (%CV).

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Elimination Terminal Half-life of Plasma MK-3866 (t1/2)	7.38 Hours Geometric Coefficient of Variation 13.3	8.23 Hours Geometric Coefficient of Variation 17.0	7.00 Hours Geometric Coefficient of Variation 12.7	14.7 Hours Geometric Coefficient of Variation 17.8	6.90 Hours Geometric Coefficient of Variation 13.0	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Volume of Distribution of Plasma MK-3866 (Vz)	40.4 Liters Geometric Coefficient of Variation 18.3	33.3 Liters Geometric Coefficient of Variation 18.0	48.0 Liters Geometric Coefficient of Variation 17.3	34.4 Liters Geometric Coefficient of Variation 29.5	48.3 Liters Geometric Coefficient of Variation 17.7	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: AUC0-inf of Plasma MK-3866	323 µM*hr Interval 260.0 to 401.0	129 µM*hr Interval 103.0 to 161.0	81.3 µM*hr Interval 70.6 to 93.7	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: AUC0-last of Plasma MK-3866	294 µM*hr Interval 241.0 to 358.0	118 µM*hr Interval 97.4 to 144.0	80.9 µM*hr Interval 70.2 to 93.3	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: AUC0-24 of Plasma MK-3866	203 µM*hr Interval 174.0 to 238.0	84.7 µM*hr Interval 74.6 to 96.1	77.8 µM*hr Interval 67.5 to 89.6	—	—	—

PRIMARY outcome

Timeframe: At the end of the infusion (0.5 hours after infusion start) on Day 1 of Period 1 and Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Ceoi of Plasma MK-3866	26.3 µM Interval 22.7 to 30.3	25.3 µM Interval 19.1 to 33.4	26.8 µM Interval 23.1 to 31.0	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Cmax of Plasma MK-3866	26.6 µM Interval 23.1 to 30.6	25.3 µM Interval 19.1 to 33.4	26.8 µM Interval 23.1 to 31.0	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: CL of Plasma MK-3866	1.23 L/hr Interval 0.989 to 1.53	3.08 L/hr Interval 2.47 to 3.85	4.87 L/hr Interval 4.23 to 5.61	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Tmax of Plasma MK-3866	0.50 Hours Interval 0.5 to 0.75	0.50 Hours Interval 0.5 to 0.5	0.48 Hours Interval 0.47 to 0.5	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: t1/2 of Plasma MK-3866	20.9 Hours Geometric Coefficient of Variation 21.6	20.0 Hours Geometric Coefficient of Variation 18.0	6.81 Hours Geometric Coefficient of Variation 13.2	—	—	—

PRIMARY outcome

Timeframe: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=7 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Vz of Plasma MK-3866	37.1 Liters Geometric Coefficient of Variation 20.0	89.1 Liters Geometric Coefficient of Variation 12.2	47.9 Liters Geometric Coefficient of Variation 18.8	—	—	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Total Amount of MK-3866 Excreted in the Urine Over 24 Hours (Ae0-24)	97.1 mg Interval 79.6 to 118.0	69.2 mg Interval 48.4 to 98.8	107 mg Interval 89.0 to 130.0	34.6 mg Interval 22.7 to 52.6	115 mg Interval 96.4 to 137.0	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t")/AUC(t'-t"), where t'-t" is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Renal Clearance (CLr) of MK-3866	2.00 L/hr Interval 1.5 to 2.66	1.08 L/hr Interval 0.801 to 1.45	2.67 L/hr Interval 2.18 to 3.27	0.377 L/hr Interval 0.2 to 0.71	2.92 L/hr Interval 2.33 to 3.65	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=9 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 1: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)	0.485 Fraction of MK-3866 Excreted Interval 0.398 to 0.592	0.346 Fraction of MK-3866 Excreted Interval 0.242 to 0.494	0.537 Fraction of MK-3866 Excreted Interval 0.445 to 0.648	0.173 Fraction of MK-3866 Excreted Interval 0.114 to 0.263	0.575 Fraction of MK-3866 Excreted Interval 0.482 to 0.686	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=2 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=2 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Total Amount of MK-3866 Excreted Unchanged in the Urine Over the Period of 24 Hours (Ae0-24)	4.31 mg Geometric Coefficient of Variation 42.6	2.21 mg Geometric Coefficient of Variation 4.4	115 mg Geometric Coefficient of Variation 24.9	—	—	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t")/AUC(t'-t"), where t'-t" is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=2 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=2 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Renal Clearance (CLr) of MK-3866	0.0474 L/hr Geometric Coefficient of Variation 8.5	0.0558 L/hr Geometric Coefficient of Variation 15.8	2.92 L/hr Geometric Coefficient of Variation 32.1	—	—	—

SECONDARY outcome

Timeframe: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=2 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=2 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)	0.0216 Fraction of MK-3866 Excreted Geometric Coefficient of Variation 42.6	0.0111 Fraction of MK-3866 Excreted Geometric Coefficient of Variation 4.4	0.574 Fraction of MK-3866 Excreted Geometric Coefficient of Variation 24.9	—	—	—

SECONDARY outcome

Timeframe: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma samples entering the dialyzer line were collected at pre-specified time points and Ca was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 0.75 hours after dosing	17.6 µM Geometric Coefficient of Variation 15.6	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 1 hour after dosing	12.0 µM Geometric Coefficient of Variation 35.8	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 1.5 hours after dosing	8.67 µM Geometric Coefficient of Variation 33.1	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 2 hours after dosing	7.25 µM Geometric Coefficient of Variation 10.8	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 2.5 hours after dosing	5.75 µM Geometric Coefficient of Variation 8.5	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 3 hours after dosing	4.32 µM Geometric Coefficient of Variation 35.8	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 3.5 hours after dosing	3.98 µM Geometric Coefficient of Variation 10.3	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 4 hours after dosing	2.98 µM Geometric Coefficient of Variation 31.8	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca) 4.5 hours after dosing	2.57 µM Geometric Coefficient of Variation 31.0	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma samples exiting the dialyzer line were collected at pre-specified time points and Cv was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 0.75 hours after dosing	8.32 µM Geometric Coefficient of Variation 20.7	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 1 hour after dosing	7.16 µM Geometric Coefficient of Variation 24.0	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 1.5 hours after dosing	5.17 µM Geometric Coefficient of Variation 25.1	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 2 hours after dosing	3.71 µM Geometric Coefficient of Variation 10.5	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 2.5 hours after dosing	2.92 µM Geometric Coefficient of Variation 11.4	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 3 hours after dosing	2.69 µM Geometric Coefficient of Variation 21.0	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 3.5 hours after dosing	2.12 µM Geometric Coefficient of Variation 25.2	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 4 hours after dosing	2.10 µM Geometric Coefficient of Variation 33.8	—	—	—	—	—
Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv) 4.5 hours after dosing	1.66 µM Geometric Coefficient of Variation 49.4	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma samples entering the dialyzer line were collected at pre-specified time points and AUCD was assessed. AUCD values were determined from the Ca versus time profile during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line During the Dialysis Period (AUCD)	29.4 µM*hr Geometric Coefficient of Variation 14.3	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC\[0.75-4.5\]Ca was assessed. AUC\[0.75-4.5\]Ca values were determined from the Ca versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Ca)	23.9 µM*hr Geometric Coefficient of Variation 19.0	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC\[0.75-4.5\]Cv was assessed. AUC\[0.75-4.5\]Cv values were determined from the Cv versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Cv)	13.6 µM*hr Geometric Coefficient of Variation 12.2	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and CLD was assessed. CLD was calculated as Q x R x (AUC\[1-4.5\]Ca - AUC\[1-4.5\]Cv) / AUC\[1-4.5\]Ca, where Q is the flow rate of blood through the dialyzer, and R is the ratio of blood drug concentration to plasma drug concentration. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Dialysis Clearance of MK-3866 Based on Plasma (CLD,Plasma)	4.81 L/hr Geometric Coefficient of Variation 201.1	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and CD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 4 hours after dosing	0.695 µM Standard Deviation 0.114	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 0.5 hours after dosing	1.07 µM Standard Deviation 1.84	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 1 hour after dosing	3.02 µM Standard Deviation 0.748	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 1.5 hours after dosing	2.29 µM Standard Deviation 0.153	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 2 hours after dosing	1.62 µM Standard Deviation 0.142	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 2.5 hours after dosing	1.30 µM Standard Deviation 0.134	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 3 hours after dosing	1.08 µM Standard Deviation 0.106	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 3.5 hours after dosing	0.894 µM Standard Deviation 0.0896	—	—	—	—	—
Part 2: Concentration of MK-3866 in Dialysate Samples (CD) 4.5 hours after dosing	0.542 µM Standard Deviation 0.251	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and AD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 0.5 hours after dosing	0.946 mg Geometric Coefficient of Variation 8.6	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 1 hour after dosing	0.736 mg Geometric Coefficient of Variation 31.8	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 1.5 hours after dosing	0.576 mg Geometric Coefficient of Variation 6.8	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 2 hours after dosing	0.408 mg Geometric Coefficient of Variation 8.7	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 2.5 hours after dosing	0.327 mg Geometric Coefficient of Variation 10.7	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 3 hours after dosing	0.272 mg Geometric Coefficient of Variation 10.3	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 3.5 hours after dosing	0.224 mg Geometric Coefficient of Variation 10.3	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 4 hours after dosing	0.173 mg Geometric Coefficient of Variation 17.2	—	—	—	—	—
Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD) 4.5 hours after dosing	0.158 mg Geometric Coefficient of Variation 13.7	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and rr was assessed. rr was calculated as CD x dialysate flow rate. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 4.5 hours after dosing	9.51 mg/hr Geometric Coefficient of Variation 13.7	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 0.5 hours after dosing	56.7 mg/hr Geometric Coefficient of Variation 8.6	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 1 hour after dosing	44.2 mg/hr Geometric Coefficient of Variation 31.8	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 1.5 hours after dosing	34.6 mg/hr Geometric Coefficient of Variation 6.8	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 2 hours after dosing	24.5 mg/hr Geometric Coefficient of Variation 8.7	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 2.5 hours after dosing	19.6 mg/hr Geometric Coefficient of Variation 10.7	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 3 hours after dosing	16.3 mg/hr Geometric Coefficient of Variation 10.3	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 3.5 hours after dosing	13.5 mg/hr Geometric Coefficient of Variation 10.3	—	—	—	—	—
Part 2: Rate of Removal of MK-3866 From the Dialysate (rr) 4 hours after dosing	10.4 mg/hr Geometric Coefficient of Variation 17.2	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and AD,total was assessed. AD,total was obtained by integrating the rr versus time profile over the dialysis session duration, using actual times relative to the start time of dialysis. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Cumulative Amount of MK-3866 Recovered From the Dialysate (AD,Total)	89.0 mg Geometric Coefficient of Variation 9.3	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2

Population: All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).

Plasma dialysis samples were collected at pre-specified time points and CLD,dialysate was assessed. CLD,dialysate was calculated as AD.total / AUCD. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Part 2: Hemodialysis Clearance of MK-3866 Based on the Dialysate(CLD,Dialysate)	6.01 L/hr Geometric Coefficient of Variation 13.2	—	—	—	—	—

SECONDARY outcome

Timeframe: Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants n=10 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Number of Participants With at Least One Adverse Event (AE)	3 Participants	3 Participants	1 Participants	1 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing

Population: All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Outcome measures

Outcome measures
Measure	Part 1: Mild Renal Impairment (RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Mild + Moderate RI) n=8 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups	Part 1: Severe Renal Impairment n=8 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Healthy Participants (Severe RI) n=7 Participants Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.	Part 1: Healthy Participants n=10 Participants Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.
Number of Participants Discontinuing the Study Due to an Adverse Event	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants

Adverse Events

Part 1: Mild Renal Impairment (RI)

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 1: Moderate Renal Impairment

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 1: Severe Renal Impairment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)

Serious events: 1 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)

Serious events: 1 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 1: Healthy Participants

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part 1: Mild Renal Impairment (RI) n=8 participants at risk Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Severe Renal Impairment n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 2, Period 1: ESRD Undergoing HD (Dosed After HD) n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.	Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD) n=7 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.	Part 1: Healthy Participants n=10 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender, and mean age and BMI of the comparator groups.
Gastrointestinal disorders Colitis ischaemic	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Nervous system disorders Thrombotic stroke	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	14.3% 1/7 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Other adverse events

Other adverse events
Measure	Part 1: Mild Renal Impairment (RI) n=8 participants at risk Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Moderate Renal Impairment n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 1: Severe Renal Impairment n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.	Part 2, Period 1: ESRD Undergoing HD (Dosed After HD) n=8 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.	Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD) n=7 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.	Part 1: Healthy Participants n=10 participants at risk Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender, and mean age and BMI of the comparator groups.
Gastrointestinal disorders Abdominal pain	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Gastrointestinal disorders Flatulence	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Nervous system disorders Dysgeusia	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	10.0% 1/10 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Nervous system disorders Headache	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	25.0% 2/8 • Number of events 2 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Renal and urinary disorders Dysuria	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Skin and subcutaneous tissue disorders Drug eruption	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).
Infections and infestations Upper respiratory tract infection	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	12.5% 1/8 • Number of events 1 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/8 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/7 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).	0.00% 0/10 • Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.
Publication restrictions are in place

Restriction type: OTHER